Adverstisement
Place your advertisement here
 

References

Abstracts of articles relevant to this topic are available through PubMed, a service of the National Library of Medicine:

Here are links to some articles relevant to this subject:

Burdette DE, Sackellares JC: Felbamate pharmacology and its use in epilepsy. Clin Neuropharmacol 1994 Oct;17(5):389-402.

Devinsky O, Faught RE, Wilder BJ, et al.: Efficacy of felbamate monotherapy in patients undergoing presurgical evaluation of partial seizures. Epilepsy Res 1995 Mar;20(3):241-6. PMID: 7796796.

Dieckhaus CM, Roller SG, Santos WL, Sofia RD, Macdonald TL: Role of glutathione s-transferases A1-1, M1-1, and P1-1 in the detoxification of 2-phenylpropenal, a reactive felbamate metabolite. Chem Res Toxicol 2001 May;14(5):511-6.

Faught E, Sachdeo RC, Remler MP, et al.: Felbamate monotherapy for partial-onset seizures: an active-control trial. Neurology 1993 Apr;43(4):688-92. PMID: 8469323.

The Felbamate Study Group in Lennox-Gastaut Syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). N Engl J Med 1993 Jan 7;328(1):29-33. PMID: 8347179.

Kaufman DW, Kelly JP, Anderson T, Harmon DC, Shapiro S: Evaluation of case reports of aplastic anemia among patients treated with felbamate. Epilepsia 1997 Dec;38(12):1261-4.

Pellock JM: Felbamate. Epilepsia 1999;40 Suppl 5:S57-62.

Thompson CD, Barthen MT, Hopper DW, et al: Quantification in patient urine samples of felbamate and three metabolites: acid carbamate and two mercapturic acids. Epilepsia 1999 Jun;40(6):769-76.

Welty TE, Privitera M, Shukla R: Increased seizure frequency associated with felbamate withdrawal in adults. Arch Neurol 1998 May;55(5):641-5.